Epizyme Inc (EPZM)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Grant C. Bogle
Employees:
250
400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE, MA 02139
617-229-5872

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma.

Data derived from most recent annual or quarterly report
Market Cap 242.366 Million Shares Outstanding164.875 Million Avg 30-day Volume 3.355 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-0.63
Price to Revenue2.7143 Debt to Equity-11.4605 EBITDA-177.227 Million
Price to Book Value0.0 Operating Margin-216.898 Enterprise Value333.494 Million
Current Ratio5.345 EPS Growth0.317 Quick Ratio4.452
1 Yr BETA 1.5013 52-week High/Low 5.8 / 0.41 Profit Margin-229.7002
Operating Cash Flow Growth8.4608 Altman Z-Score-7.801 Free Cash Flow to Firm -165.952 Million
View SEC Filings from EPZM instead.

View recent insider trading info

Funds Holding EPZM (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding EPZM

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-08-12:
    Item 1.02: Termination of a Material Definitive Agreement
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.01: Changes in Control of Registrant
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-27:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-24:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
  • 8-K: filed on 2022-05-19:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-04-06:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-03-15:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-01:
    Item 2.02: Results of Operations and Financial Condition
    Item 2.05: Cost Associated with Exit or Disposal Activities
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-01-27:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    GOLDFISCHER CARL

    • Director
    0 2022-08-12 2

    BATE KENNETH

    • Director
    0 2022-08-12 2

    MOTT DAVID M

    • Director
    0 2022-08-12 4

    CONROY KEVIN T

    • Director
    0 2022-08-12 4

    LEGORRETA PABLO G.

    RP MANAGEMENT, LLC

    RPI FINANCE TRUST

    ROYALTY PHARMA INVESTMENTS 2019 ICAV

    • Director
    • 10% Owner
    0 2022-08-12 2

    BEVERIDGE, ROY A

    • Director
    0 2022-08-12 4

    BOGLE GRANT C. PRESIDENT AND CEO

    • Officer
    • Director
    0 2022-08-12 3

    KUTOK JEFFERY CHIEF SCIENTIFIC OFFICER

    • Officer
    0 2022-08-12 4

    GIORDANO MICHAEL F

    • Director
    0 2022-08-12 2

    AGARWAL SHEFALI

    • SEE REMARKS
    0 2022-08-12 4

    BEAULIEU JOSEPH SEE REMARKS

    • Officer
    0 2022-08-12 4

    KORN JERALD CHIEF OPERATING OFFICER

    • Officer
    0 2022-08-12 3

    RICHON VICTORIA

    • Director
    0 2022-08-12 2

    STUCKLEY CAROL

    • Director
    0 2022-08-12 2

    LEGORRETA PABLO G.

    RP MANAGEMENT, LLC

    RPI FINANCE TRUST

    • Director
    • 10% Owner
    31,930,464 2022-01-31 2

    ROYALTY PHARMA INVESTMENTS 2019 ICAV

    • Director
    • 10% Owner
    22,666,667 2022-01-31 0

    ROS MATTHEW SEE REMARKS

    • Officer
    245,491 2021-08-16 0

    ALLEN ANDREW R

    • Director
    61,119 2021-06-11 0

    BAZEMORE ROBERT B PRESIDENT & CEO

    • Officer
    • Director
    335,867 2021-02-01 0

    TOMBESI PAOLO CHIEF FINANCIAL OFFICER

    • Officer
    54,486 2021-02-01 0

    VAKIENER VICTORIA CHIEF COMMERCIAL OFFICER

    • Officer
    53,502 2021-02-01 0

    POPS RICHARD F

    • Director
    0 2020-05-29 0

    LEGORRETA PABLO G.

    • Director
    0 2019-11-06 0

    SEIDENBERG BETH C

    • Director
    4,124,036 2019-06-30 0

    GRAF SUSAN E CHIEF BUSINESS OFFICER

    • Officer
    0 2018-02-09 0

    FLEMING SUZANNE SVP

    • Officer
    0 2018-02-09 0

    HO PETER TAI-CHING CHIEF DEVELOPMENT OFFICER

    • Officer
    10,123 2017-10-24 0

    SINGER ANDREW E. EVP & CFO

    • Officer
    45,446 2017-08-09 0

    COPELAND ROBERT A PRESIDENT OF RESEARCH AND CSO

    • Officer
    31,538 2017-06-06 0

    BARRIS PETER J

    • 10% Owner
    6,261,599 2016-01-12 0

    BARRETT M JAMES

    • 10% Owner
    6,260,851 2016-01-12 0

    KERINS PATRICK J

    • 10% Owner
    6,261,502 2016-01-12 0

    SANDELL SCOTT D

    • 10% Owner
    6,261,502 2016-01-12 0

    KOLLURI KRISHNA KITTU

    • 10% Owner
    6,260,851 2016-01-12 0

    BASKETT FOREST

    • 10% Owner
    6,260,851 2016-01-12 0

    BAY CITY CAPITAL LLC

    BAY CITY CAPITAL FUND V CO-INVESTMENT FUND, L.P.

    BAY CITY CAPITAL FUND V, L.P.

    BAY CITY CAPITAL MANAGEMENT V LLC

    • 10% Owner
    6,751,513 2016-01-12 0

    WELLER HARRY R

    • 10% Owner
    6,260,851 2016-01-12 0

    NEW ENTERPRISE ASSOCIATES 13 LP

    NEA PARTNERS 13, LIMITED PARTNERSHIP

    NEA 13 GP, LTD

    • 10% Owner
    6,260,851 2016-01-12 0

    VISWANATHAN RAVI

    • 10% Owner
    6,260,851 2016-01-12 0

    GOULD ROBERT J

    • Director
    0 2015-12-29 0

    GARBACZ STEPHEN PRINCIPAL ACCOUNTING OFFICER

    • Officer
    13,073 2014-11-03 0

    HEDRICK ERIC CHIEF MEDICAL OFFICER

    • Officer
    429 2014-10-15 0

    RHODES JASON P PRESIDENT, CFO AND TREASURER

    • Officer
    138,000 2014-09-22 0

    DRANT RYAN D

    • 10% Owner
    406,500 2014-08-14 0

    NEW ENTERPRISE ASSOCIATES 13 LP

    • 10% Owner
    5,149,740 2014-08-14 0

    NEA PARTNERS 13, LIMITED PARTNERSHIP

    NEA 13 GP, LTD

    • 10% Owner
    5,149,740 2014-08-14 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    EPIZYME INC EPZM 2022-08-12 22:15:03 UTC 0.9869 1.3331 100000
    EPIZYME INC EPZM 2022-08-12 21:45:04 UTC 0.9869 1.3331 100000
    EPIZYME INC EPZM 2022-08-12 21:15:04 UTC 0.9869 1.3331 100000
    EPIZYME INC EPZM 2022-08-12 20:45:04 UTC 1.0322 1.2878 100000
    EPIZYME INC EPZM 2022-08-12 20:15:05 UTC 1.0322 1.2878 100000
    EPIZYME INC EPZM 2022-08-12 19:45:03 UTC 1.0322 1.2878 100000
    EPIZYME INC EPZM 2022-08-12 19:15:05 UTC 1.0322 1.2878 100000
    EPIZYME INC EPZM 2022-08-12 18:45:03 UTC 0.9868 1.3332 100000
    EPIZYME INC EPZM 2022-08-12 18:15:04 UTC 0.9868 1.3332 100000
    EPIZYME INC EPZM 2022-08-12 17:45:04 UTC 0.9868 1.3332 100000
    EPIZYME INC EPZM 2022-08-12 17:15:05 UTC 0.9868 1.3332 250000
    EPIZYME INC EPZM 2022-08-12 16:45:04 UTC 0.9868 1.3332 250000
    EPIZYME INC EPZM 2022-08-12 16:15:04 UTC 0.9868 1.3332 250000
    EPIZYME INC EPZM 2022-08-12 15:45:04 UTC 0.9868 1.3332 250000
    EPIZYME INC EPZM 2022-08-12 15:15:05 UTC 0.9868 1.3332 250000
    EPIZYME INC EPZM 2022-08-12 14:45:04 UTC 1.2204 1.0996 200000
    EPIZYME INC EPZM 2022-08-12 14:15:05 UTC 1.2204 1.0996 200000
    EPIZYME INC EPZM 2022-08-12 13:45:04 UTC 0.9316 1.3884 200000
    EPIZYME INC EPZM 2022-08-12 13:15:04 UTC 0.9316 1.3884 200000
    EPIZYME INC EPZM 2022-08-12 12:45:04 UTC 0.9316 1.3884 100000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Trust for Professional Managers- Convergence Market Neutral Fund EPZM -5172.0 shares, $-67236.0 2020-08-31 N-PORT
    FundVantage Trust- Gotham Enhanced Index Plus Fund EPZM -139.0 shares, $-2155.89 2020-03-31 N-PORT
    FundVantage Trust- Gotham Defensive Long Fund EPZM -147.0 shares, $-2279.97 2020-03-31 N-PORT
    FundVantage Trust- Gotham Index Plus All-Cap Fund EPZM -183.0 shares, $-2838.33 2020-03-31 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments